longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Enlivex

ENLV

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 0.00, above the reasonable range, cheaper than 10.28% of the time in the past 5 years, and the industry ranks 1/603, the industry Median -2.26.

0.0026xP/E
$0.48Stock price
$182.43Earnings per share
0.0026xP/E
Stock price$0.48Earnings per share$182.43

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.78x
Typical range
-3.68x–-1.08x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.56x42.44%$5.02B
ACADUSAcadia Pharma
9.16x73.45%$3.48B
PURRUSHyperliquid Strategies
9.21x84.74%$2.36B
ADMAUSAdma Biologics
13.20x35.42%$2.23B
AUPHUSAurinia Pharma
6.96x54.40%$2.18B
LKFTUSLakefront Biotherapeutics
2.77x86.19%$1.92B
ANABUSAnaptysbio
5.75x1,051.46%$1.51B
VORUSVor BioPharma
1.73x89.77%$1.08B
MGTXUSMeiraGTx
13.53x122.03%$1.07B
ABUSUSArbutus Pharma
6.03x533.09%$923.65M
RIGLUSRigel Pharma
2.84x83.91%$913.26M
BVNRYUSBavarian Nordic A/S
3.47x--$832.02M
IRWDUSIronwood Pharma
5.29x715.55%$687.40M
AGENUSAgenus
4.85x--$445.25M
CUVLUSClinuvel Pharmaceuticals
12.91x--$296.01M
QTTBUSQ32 Bio
8.40x162.67%$283.70M
CGENUSCompugen
6.33x173.68%$222.60M
PLXUSProtalix Biotherap
11.44x400.00%$216.74M
VXRTUSVaxart
2.84x328.57%$109.49M
RLYBUSRallybio
2.01x131.45%$91.45M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.